ROS1 and non-small cell lung carcinoma: We further analysed mOS in metastatic non-squamous NSCLC patients according to whether or not they had a targeted tyrosine kinase inhibitor (TKI) therapy option (i.e., known EGFR kinase domain mutation or ALK/ROS1 translocations).